SpagoNanomedical select ChemConnection for SpagoPix production to supply clinicaltrials
Spago Nanomedical AB has signed an agreement with ChemConnection BV, a well-established contract manufacturer with extensive experience in the GMP-production of nanomedical products, for the manufacture of the SpagoPix product candidate SN132D for clinical trials.
The SpagoPix project is advancing towards clinical trials and the product candidate SN132D is currently undergoing regulatory preclinical tests to generate the toxicity and safety data required to initiate human studies.
The production of material will commence in the first half of 2018. Tech transfer in which Spago Nanomedical transfers the production process developed by the company during the past year, starts immediately.
"We look forward to starting the GMP production of SN132D and continue preparations for clinical trials," says Oskar Axelsson, CSO of Spago Nanomedical.
"We are proud that we can contribute to the development of this exciting new product with the manufacture of clinical batches" says Gerjan Kemperman, CEO of ChemConnection.
For further information, contact Mats Hansen, CEO Spago Nanomedical AB, +46 767 764294, mats.hansen@spagonanomedical.se.
Spago Nanomedical (AktieTorget Stockholm: SPAG) develops nanomaterials for cancer diagnostics and therapy. The company´s development activities are primarily focused on the cancer selective MRI-contrast agent SpagoPix, and the Tumorad®-project for cancer selective radionuclide therapy of cancer. The business concept of Spago Nanomedical is to develop projects from explorative to regulatory preclinical or early clinical phase, and then out-license or enter partnership for continued development of the projects to market launch. Spago Nanomedical collaborates with well-established and reputable patent consultants to continuously strengthen the intellectual property protection of the projects. For more information, see www.spagonanomedical.se.
SpagoPix is a contrast agent based on nanoparticles and manganese aiming to improve cancer diagnostics using magnetic resonance imaging (MRI). By offering high precision and excellent signal amplification in tumors and metastases correct diagnosis of cancer with MRI is facilitated. Improved diagnostic capabilities may increase the chances of efficient treatment for the patients.
The information in this press release is such that Spago Nanomedical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU, 596/2014). The information was submitted for publication, through the agency of the contact person set out above, on 5 December, 2017.
Tags: